



Improving healthcare decisions

Russia St. Petersburg Regional Chapter Annual Report - 2017

Chapter	St. Petersburg
President	Alexey Kolbin, MD, PhD, Doctor of Medical Sciences, professor, Head of the Department of Clinical Pharmacology First Pavlov State Medical University of St.Peterburg, alex.kolbin1971@gmail.com
President-Elect	Sergey Zyryanov, MD, PhD, Doctor of Medical Sciences, professor, Head of the Department of Pharmacology of RUDN University, sergey.k.zyryanov@gmail.com
Past President	
Secretary	Alexey Kurylev, MD, Department of Clinical Pharmacology First Pavlov State Medical University of St.Peterburg, alexey-kurilev@yandex.ru
Treasurer	Alexey Kurylev, MD, Department of Clinical Pharmacology First Pavlov State Medical University of St.Peterburg, alexey-kurilev@yandex.ru
Director	Dmitry Belousov, MD, Journal "Good clinical practice" (chief editor), clinvest@mail.ru
When are elections held for your Chapter's Board?	09. 2017
Regional Chapter Members - 2017	13
Regional Chapter Members - 2016	14
Notes re Chapter members	
Full ISPOR members (those paying dues to ISPOR Headquarters)	13
Does your Chapter collect membership dues or fees from individuals for local Chapter membership?	No
Benefits Chapter offer to members	We give information about new methods in HTA, organize educational meetings, find new prospects in HTA.
Chapter's accomplishments in 2017 with regard to membership recruitment, retention, and engagement.	
Academia%	70
Government/HTA Agency%	5
Industry - Pharmaceutical/Medical Device/Diagnostics/ Biotech%	1
Consulting%	0
Clinicians%	20
Student%	4
Other%	

Chapter's accomplishments in 2017 with regard to education and training.

1. XXI Annual Scientific Session of the Pharmacology Institute named after A.V. Valdman Pavlov First Saint Petersburg State Medical University. HTA section - Evaluation of medical technologies in Russia - from theory to practice. Saint Petersburg. 2. V Russian Conference with international participation. "Current issues of preclinical and clinical trials of medicines, biomedical cellular products and clinical research of medical devices". Ministry of Health; Pavlov First Saint Petersburg State Medical University. HTA section - Prognosis of clinical efficacy based on clinical studies. Saint Petersburg. 3. III St. Petersburg International Oncology Forum «White Nights - 2017». Pharmacoeconomics in oncology Session. Ministry of Health; Russian Academy of Sciences; Healthcare Committee of St. Petersburg. HTA section - Cost of additional effectiveness in oncology. The data from restrictive lists in the Russian Federation, years 2014 - 2015. Saint Petersburg

Chapter's accomplishments in 2017 with regard to research.

1. Pharmacoeconomic analysis of the use of parnapanarin (Fluxum®) for the prevention of venous thromboembolic complications in surgical interventions and for the treatment of superficial thrombophlebitis 2. Comparative pharmacoeconomic assessment of the type 2 diabetes treatment with insulin degludec and insulin glargine in basal-bolus insulin therapy 3. Complex clinical and economic assessment of omalizumab in severe uncontrolled bronchial asthma in Russia 4. Pharmacoeconomic characteristics of ixabepilone (Ixempra) monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabine 5. Comparative pharmacoeconomic evaluation of basal-bolus insulin therapy with insulin degludec and insulin glargine in diabetes 2 type treatment 6. Evaluation of final and surrogate endpoints of drugs included in reimbursement lists in 2016 7. Pharmacoeconomic analysis of Flemoclav Solutab® use in adult patients with acute sinusitis in routine outpatient clinical practice in Russia 8. Pharmacoeconomic analysis of brentuximab vedotin therapy in relapsed or refractory CD30+ systemic anaplastic large cell lymphoma in patients over 18 years of age: health budget impact analysis 9. Pharmacoepidemiology of antimicrobial agents in pregnant women: a non-interventional retrospective study 10. Pharmacoeconomic analysis of dexamethasone intravitreal implant for the treatment of diabetic macular edema in Russia 11. Pharmacoepidemiology of Antimicrobials in Neonatology in Russia, Retrospective Analysis of Medical Records 12. Pharmacoepidemiology of Antimicrobials in Pregnant Women And Women After Childbirth In Russia, Retrospective Analysis of Medical Records. 13. Health economic analysis of vemurafenib and dabrafenib in patients with metastatic or unresectable melanoma with BRAF V600 mutation 14. Economic assessment of the effectiveness and safety of the commonly practiced perioperative antibiotic prophylaxis (based on an earlier epidemiological survey of multidisciplinary hospitals) 15. Pharmacoeconomic analysis of trastuzumab emtansine comparing to lapatinib+capecitabine in patients with HER2+ breast cancer and central nervous system metastases 16. Economic Consequences of Common Practice Community Acquired Pneumonia Treatment Based on Epidemiological Study at Multidisciplinary Hospitals 17. Cost-effectiveness analysis of the current practice of antibiotic therapy of community-acquired pneumonia in multidisciplinary hospitals 18. Comparative pharmacoeconomic evaluation of the treatment of type 2 diabetes mellitus with insulin degludec and insulin glargine in basal-bolus insulin therapy 19. Ranking Algorithm for Medical Research Results Based on the Levels of Evidence at the Stage of Getting Answers to Search Queries 20. Pharmacoeconomic Analysis of Trastuzumab Emtansine in Patients with Metastatic Breast Cancer and Central Nervous System Metastases 21. Pharmacoeconomic Analysis of

Obinutuzumab Plus Chlorambucil in Patients with Previously Untreated Chronic Lymphocytic Leukemia and Coexisting Conditions 22. Pharmacoeconomic Analysis of Ixabepilone Monotherapy in Patients with Advanced or Metastatic Breast Cancer Resistant To Anthracyclines, Taxanes and Capecitabine 23. The Analysis Of Final And Surrogate Effectiveness Criteria Used In Health Economic Studies Of Drugs Submitted Into The Reimbursement In Russia In 2016 24. Analysis of Effectiveness Criteria In Pharmacoeconomic Studies of Antimicrobial Therapeutic Agents Proposed for Inclusion In The Essential Drug List (RUSSIA) In 2014-2016 25. Decision modelling for the evaluation of diabetes outcomes 26. Comparative pharmacoeconomic evaluation of the use of afatinib and gefitinib in therapy for lung cancer 27. Pharmacoeconomic study of the use of thrombopoietin receptor agonists in adult patients with chronic idiopathic thrombocytopenic purpura in the Russian Federation 28. Comparative evaluation of clinical and economic efficiency of paliperidone in various dosage forms used in patients with schizophrenia 29. Cost-effectiveness analysis of pembrolizumab versus targeted therapies in advanced melanoma 30. Clinical and pharmacoeconomic aspects of anti-TNF therapy change for medical reasons 31. Evaluation of the health care budget impact of secukinumab treatment in patients with ankylosing spondylitis 32. Pharmacoeconomic Effectiveness of the Inclusion of Glycopyrronium Bromide into the Program of Reimbursement of Essential Drugs for Patients with Chronic Obstructive Pulmonary Disease 33. Burden of Childhood Rotavirus Disease in the Outpatient Setting of the Russian Federation 34. The burden of rotavirus gastroenteritis, as the rationale for routine vaccination 35. Protease inhibitor narnraprevir in therapy of hepatitis C virus genotype 1 infection in treatment-naïve patients without cirrhosis: pharmacoeconomic evaluation 36. Cost-effectiveness of antiviral therapy in treatment-naïve patients with chronic hepatitis C (genotype 1) 37. The averted costs due to influenza vaccination with trivalent and quadrivalent vaccines 38. Pharmacoeconomic aspects of macitentan in the therapy of pulmonary arterial hypertension 39. Comparative analysis of laparoscopic and laparoscopic panhysterectomy costs in patients with early stage endometrial cancer 40. Pharmacoeconomic aspects of combined treatment of advanced stage of Parkinson's disease 41. Pharmacoeconomic aspects of biosimilars 42. Pharmacoeconomic aspects of non-small cell lung cancer immunotherapy 43. Pharmacoeconomic Aspects of Combined Treatment of Advanced Parkinson's Disease 44. Immunotherapy of non-small cell lung cancer: clinical and pharmacoeconomic aspects 45. Clinical and economic evaluation of inhalation anesthetics 46. Pharmacoeconomic assessment of intermittent and continuous renal replacement therapy 47. Comparative pharmacoeconomic analysis of anti-VEGF therapy for age-related macular degeneration 48. Pharmacoeconomic analysis of ranibizumab and afibbercept for treatment of diabetic macular edema 49. Pharmacoeconomic assessment of intermittent and continuous renal replacement therapy 50. Cost of type 2 diabetes mellitus in Russian Federation: results of pharmacoepidemiological study FORSIGHT-DM2 51. Evaluation of direct cost in case of insulin glargine-100 switching to insulin glargine-300 in diabetes mellitus in real clinical practice 52. Cost-effectiveness and cost-utility analysis of gene therapy drug Neovasculgen in the treatment of chronic lower limb ischemia 53. The cost-effectiveness, cost-utility, and influence on the budget of the Russian Federation analysis of replacement of the I generation 5TH3 receptor antagonists with palonosetron for the prevention of chemotherapy-induced nausea and vomiting 54. Pharmacoeconomical evaluation of brivaracetam – the new drug for the adjunctive treatments in uncontrolled focal epilepsy – in Russia 55. Use of Creon® Micro in the treatment of

Chapter's accomplishments in 2017 with regard to policy-related activities.

Chapter's accomplishments with regard to Chapter meetings, workshops, or conferences in 2017.

exocrine pancreatic insufficiency in children with cystic fibrosis. Budget impact analysis 56. The economic consequences of the introduction of Creon Micro into the basic therapy of exocrine pancreatic insufficiency in children cystic fibrosis 57. Use of inhibitor of cycline-dependent kinase 4/6 (palbociclib) in treatment of metastatic breast cancer.

1. Participation in the operation of the Working Group on Monitoring Law Enforcement Practices of the Rules for the Compiling Restrictive Drug Lists of the Russian Federation Ministry of Health

1. XXI Annual Scientific Session of the Pharmacology Institute named after A.V. Valdman Pavlov First Saint Petersburg State Medical University. Evaluation of medical technologies in Russia - from theory to practice. Saint Petersburg 2.VIII Scientific and Practical Conference "Rational Pharmacotherapy in Therapeutic Practice" with symposium "Respiratory system Disorders". Russian Academy of Medical Sciences, Healthcare Committee of St. Petersburg. Does the choice of medicines belong to a doctor, a patient or a state? Saint Petersburg 3.Safety of Medicines - Acute Fundamental and Applied Questions. Healthcare Committee of St. Petersburg. Importance of drug safety in health technology assessment. Saint Petersburg. 4. 5th Interregional Scientific and Practical Symposium "Pharmacoeconomics of Chronic Viral Infections. Issues of economics in epidemiology, prevention, diagnosis and clinic of HIV infection and chronic hepatitis". Russian Academy of Medical Sciences, Healthcare Committee of St. Petersburg. Pharmacoeconomics in the Russian Federation: from theory to practice. The Role of Pharmacoeconomics in Decision Making in Epidemiology and Infectious Pathology. Saint Petersburg 5.VI St. Petersburg International Forum of Otorhinolaryngologists of Russia. Ministry of Health, Healthcare Committee. Pharmacoeconomic aspects of the antibiotic therapy choice. Saint Petersburg 6. Interregional conference "Topical issues of clinical pharmacology and drug provision" (within the framework of the All-Russian meeting "Topical issues of clinical pharmacology and drug provision") Ministry of Health. Performance indicators used in clinical and economic studies of medicines proposed for inclusion in restrictive lists in Russia. Voronezh 7. Interregional conference "Topical issues of clinical pharmacology and drug provision" (within the framework of the All-Russian meeting "Topical issues of clinical pharmacology and drug provision") Ministry of Health. Differential approach to the accreditation of specialists of various qualification categories in the field of clinical pharmacology. Voronezh 8. V Russian Conference with international participation "Current issues of preclinical and clinical trials of medicines, biomedical cellular products and clinical research of medical devices" Ministry of Health; Pavlov First Saint Petersburg State Medical University. Prognosis of clinical efficacy based on clinical studies. Saint Petersburg 9.IX Congress of Russian Oncology Association Russian Oncology Association; Ministry of Health of the Russian Federation; Russian Academy of Sciences. The problem of selecting generics in oncology. The prospects of using multi-criteria analysis methodology. Ufa 10. III St. Petersburg International Oncology Forum «White Nights - 2017». Pharmacoeconomics in oncology Session. Ministry of Health; Russian Academy of Sciences; Healthcare Committee of St. Petersburg. Cost of additional effectiveness in oncology. The data from restrictive lists in the Russian Federation, years 2014 - 2015. Saint Petersburg 11. St. Petersburg Septic Forum. Healthcare Committee; Local Compulsory Medical Insurance Fund Performance indicators used in clinical and economic studies of antimicrobial agents proposed for inclusion in restrictive lists in Russia. Saint Petersburg 12. XII International Scientific Congress "Rational Pharmacotherapy"-2017. Healthcare

Committee. Analysis of effectiveness criteria for pharmacoconomic studies of drugs used in diabetes mellitus. Data of Russian restrictive lists. Saint Petersburg 13. "HIV infection and immunosuppression. Epidemiology, clinic and modern strategies. Heavy and comorbid forms of HIV infection". Russian Academy of Medical Sciences. The modern choice of the generic drugs. International recommendations. Saint Petersburg 14. VIII Siberian Medical and Pharmaceutical Forum. The Government of Krasnoyarsk Territory. How much does the additional efficacy in oncology in Russia cost? Krasnoyarsk 15. Regional interdisciplinary practical seminar "Issues of rendering assistance to HIV-infected women and their children in St. Petersburg". Healthcare Committee. Pharmacoconomic aspects of the prevention and treatment of infectious diseases. Saint Petersburg 16. Regional interdisciplinary practical seminar "Issues of rendering assistance to HIV-infected women and their children in St. Petersburg". Healthcare Committee. Pharmacoconomic aspects of perinatal HIV transmission. Saint Petersburg 17. IX Annual All-Russian Congress with International Participation on Infectious Diseases. Russian Academy of Medical Sciences. Budget impact analysis of various schemes of antiviral treatment of chronic hepatitis C. Moscow 18. Eurasian Expert Council "Modern Approaches to Health Technology Assessment in Case of Preventive Vaccination". Eurasian Expert Council. Basics of prognosis of pharmacoeconomic effectiveness of children immunization against vaccine-preventable infections in the Russian Federation. Astana 19. 5th Interregional Scientific and Practical Symposium "Pharmacoconomics of Chronic Viral Infections. Issues of economics in epidemiology, prevention, diagnosis, and clinic of HIV infection and chronic hepatitis". Russian Academy of Medical Sciences. Pharmacoconomics of HIV therapy. Saint Petersburg. 20. Workshop at the Petrov Research Institute of Oncology on the topic "The Place of Tablet Cytostatics in the Treatment of Malignant Neoplasms". FSBI «Petrov Research Institute of Oncology» of the Ministry of Healthcare of the Russian Federation. Pharmacoeconomic aspects of malignant neoplasms therapy with oral vinorelbine. Saint Petersburg 21. Scientific conference "Pharmacoconomics in oncology and oncohematology". Russian Academy of Medical Sciences. Pharmacoeconomic aspects of metastatic melanoma therapy. Saint Petersburg 22. III Moscow city Conference on Clinical Pharmacology and Rational Pharmacotherapy "Votchalovsky's Readings". Healthcare Committee. Pharmacoeconomic aspects of metastatic melanoma therapy. Moscow 23. IV Russian symposium with international participation "Papillomavirus infection and cancer: a unified system of epidemiological surveillance and prevention". Russian Academy of Medical Sciences. Pharmacoeconomic aspects of vaccination against papillomavirus infection. Saint Petersburg 24. International Oncology Forum "White Nights 2017". Russian Academy of Medical Sciences. Innovative medical technologies in oncology: willingness to pay threshold. Saint Petersburg 25. ERS International conference. ERS. Pharmacoeconomic aspects of drug susceptibility testing of M. tuberculosis using automated liquid culture systems and solid media. Milano 26. Scientific workshop "Topical issues of immunotherapy of solid tumors". Russian Academy of Medical Sciences. Pharmacoeconomic aspects of malignant neoplasms immunotherapy. Saint Petersburg 27. II St. Petersburg Forum on HIV Infection "Modern Aspects of Prevention, Diagnosis and Treatment". Russian Academy of Medical Sciences. Costs optimization for antiviral therapy - pharmacoeconomic analysis of available treatment regimens for HCV genotype 1. Saint Petersburg 28. XII International Scientific Congress "Rational Pharmacotherapy". Healthcare Committee. Pharmacoeconomic aspects of immunotherapy of metastatic melanoma and non-small cell lung cancer. Saint Petersburg 29. International

Scientific conference "HIV infection and immunosuppression. Epidemiology, clinic and modern strategies. Heavy and comorbid forms of HIV infection". Russian Academy of Medical Sciences. Pharmacoeconomics and HIV medicine. Saint Petersburg 30. All-Russian annual congress "Infectious Diseases in Children: Diagnosis, Treatment and Prevention". Russian Academy of Medical Sciences. Pharmacoeconomic and clinical advantages of quadrivalent influenza vaccines. Saint Petersburg 31. All-Russian scientific and practical conference of phthisiologists with international participation "Interdisciplinary approach to solving the problem of tuberculosis". Russian Academy of Medical Sciences. Pharmacoeconomic aspects of diagnostics and control of pulmonary tuberculosis therapy using inoculation on liquid (BACTEC MGIT) and solid media. Moscow 32. XI Congress of the All-Russian Public Organization "All-Russian Scientific-Practical Society of Epidemiologists, Microbiologists and Parasitologists" "Ensuring Epidemiological Well-Being: Challenges and Solutions". Ministry of Health. Pharmacoeconomic ground of vaccination against rotavirus infection in the Russian Federation. Moscow 33. All-Russian annual scientific conference "Unresolved issues of etiopathic therapy of topical infections". Healthcare Committee. Pharmacoeconomics of the 4-valent influenza vaccine. Saint Petersburg 34. III St. Petersburg International Oncology Forum «White Nights - 2017». Russian Academy of Medical Sciences. ABC / VEN-analysis: the role and place in oncology. Saint Petersburg 35. XVI Assembly "Health of Moscow". Russian Academy of Medical Sciences. Tactics of patients management of older age groups with comorbid pathology. Moscow 36. XIV annual interregional conference "Topical issues of quality assurance of medicinal and medical care". Russian Academy of Medical Sciences. Clinical and economic evaluation of the pharmacotherapy of COPD in the real world practice of Russian public healthcare. Sochi 37. Scientific Conference "Health Technology Assessment for Orphan Diseases" Ministry of Health. Potentialities and difficulties associated with the use of biosimilars in patients with LSD and CNS disorders. Saint Petersburg 38. Scientific Conference "Treatment of schizophrenia in a new model for the provision of mental health care". Ministry of Health. Pharmacoeconomic aspects of paliperidone palmitate. Moscow 39. XI National Congress with international participation "Development of pharmacoeconomics and pharmacoepidemiology in the Russian Federation" - "Pharmacoeconomics - 2017". Ministry of Health. Pharmacotherapy of ACS with conservative treatment tactics. Ekaterinburg 40. All-Russian meeting "Topical issues of clinical pharmacology and drug provision". Ministry of Health. Modern pharmacotherapy of nonsmall cell lung cancer: how effective are the costs? Voronezh 41. Conference "Issues of Diagnosis and Treatment of Melanoma and Skin Tumors". Association of specialists on problems of melanoma. Pharmacoeconomic evaluation of the use of Zelboraf (vemurafenib) in the treatment of patients with metastatic or unresectable skin melanoma with BRAF V600 mutation. Moscow 42. The best based on the materials of international conferences and symposiums 2017: WEST" Russian Society of Clinical Oncology. Questions of the economic feasibility of late lines of drug therapy for breast cancer. Sochi 43. "Topical issues of clinical pharmacology and drug provision". Association of Clinical Pharmacologists of the Russian Federation. Health economic analysis of vemurafenib in patients with metastatic or unresectable melanoma with BRAF V600 mutation. Voronezh 44. IX Congress of Russian Oncology Association. Russian Oncology Association; Ministry of Health of the Russian Federation. Patient accessibility to therapy in the third and subsequent lines of treatment for metastatic cancer. Ufa 45. IX Congress of Russian Oncology Association. Russian Oncology Association; Ministry of Health of the Russian Federation. Can innovative approaches to the

Articles published in ISPOR's publication in 2017 - *Value in Health*, *Value in Health Regional Issues*, *Value and Outcomes Spotlight*, and ISPOR Regional newsletters by members in your Chapter.

Contributions to ISPOR Conferences and Events by Chapter members in 2017. Include workshops, poster, and podium sessions.

Describe any regional patient engagement activities.

Activities organized for students or new professionals.

therapy of metastatic breast cancer be economically feasible? Ufa 46. III Oncology Forum of the Southern Federal District of Russia. Russian Oncology Association. Breast cancer. Pharmacoeconomic aspects of the innovative therapy. Pyatigorsk 47. 12th international scientific congress "Rational Pharmacotherapy". Healthcare committee of Saint Petersburg, Regional NGO "Professional medical Association of clinical pharmacologists of Saint Petersburg". Clinical-economic aspects of pharmacotherapy for diabetic macular edema. Saint Petersburg. 48. I All-Russian Conference "The Real Way from Scientific Developments to Drugs", November 2, 2017. Post-marketing surveillance studies. Moscow

1. Pharmacoeconomic Analysis of Dexamethasone Intravitreal Implant for the Treatment 2. Pharmacoeconomic Analisys of Trastuzumab Emtanzine in Patients with Metastatic Breast Cancer and Central Nervous System Metastases 3. Pharmacoeconomic Analisys of Obinutuzumab Plus Chlorambucil in Patients with Previously Untreated Chronic Lymphocytic Leukemia and Coexisting Conditions 4. Pharmacoeconomic Analisys of Ixabepilone Monotherapy in Patients with Advanced or Metastatic Breast Cancer Resistant To Anthracyclines, Taxanes and Capecitabine 5. The Analysis Of Final And Surrogate Effectiveness Criteria Used In Health Economic Studies Of Drugs Submitted Into The Reimbursement In Russia In 2016 6. Analysis of Effectiveness Criteria In Pharmacoeconomic Studies of Antimicrobial Therapeutic Agents Proposed for Inclusion In The Essential Drug List (RUSSIA) In 2014-2016
1. ISPOR 22nd Annual International meeting. ISPOR. POSTER - Pharmacoeconomic Analysis of Dexamethasone Intravitreal Implant for the Treatment. May 20-24, 2017, Boston, MA, USA.
2. 20th European Congress. ISPOR. POSTER - Pharmacoeconomic Analisys of Trastuzumab Emtanzine in Patients with Metastatic Breast Cancer and Central Nervous System Metastases. November 6-9, 2017, Glasgow, Scotland
3. 20th European Congress. ISPOR. POSTER - Pharmacoeconomic Analisys of Obinutuzumab Plus Chlorambucil in Patients with Previously Untreated Chronic Lymphocytic Leukemia and Coexisting Conditions. November 6-9, 2017, Glasgow, Scotland
4. 20th European Congress. ISPOR. POSTER - Pharmacoeconomic Analisys of Ixabepilone Monotherapy in Patients with Advanced or Metastatic Breast Cancer Resistant To Anthracyclines, Taxanes and Capecitabine. November 6-9, 2017, Glasgow, Scotland
5. 20th European Congress. ISPOR. POSTER - The Analysis Of Final And Surrogate Effectiveness Criteria Used In Health Economic Studies Of Drugs Submitted Into The Reimbursement In Russia In 2016. November 6-9, 2017, Glasgow, Scotland
6. 20th European Congress. ISPOR. POSTER - Analysis of Effectiveness Criteria In Pharmacoeconomic Studies of Antimicrobial Therapeutic Agents Proposed for Inclusion In The Essential Drug List (RUSSIA) In 2014-2016. November 6-9, 2017, Glasgow, Scotland

We have students science group consist from students of First Pavlov State Medical University of St.Peterburg

Chapter affiliations with any institutions, universities, government, or associations (other than ISPOR).	1. Participation in the work of the Clinical Pharmacologist Russian Association; 2. Participation in the work of the Training and Methodological Committee for Clinical Pharmacology under the Russian Federation Ministry of Health; 3. In 2017, on the Chapter initiative, the ASSOCIATION OF SPECIALISTS IN THE FIELD OF HEALTH TECHNOLOGY ASSESSMENT was registered in the Russian Federation Ministry of Justice
Does your Chapter have any agreements of sponsorship arrangements with any for-profit companies, governments, health authorities, or associations?	No
Chapter (as a group, not as individual members) formal comments or responses to any government or health authority.	1. Participation in the operation of the Working Group on Monitoring Law Enforcement Practices of the Rules for the Compiling Restrictive Drug Lists of the Russian Federation Ministry of Health
Chapter Groups	Student, HTA, Research
HTA in your Chapter's country or region.	<p>Our country/region requires HTA and the Chapter's individual members are involved as experts in the national/regional HTA organizations.</p> <p>Our Chapter provides training/education in HTA.</p> <p>Our country/region requires HTA and the Chapter participates in the development/update of national/regional HTA guidelines.</p>
Is your Chapter officially registered with regional authorities in your country?	No
Does your Chapter employ paid administrative or management staff (Association Management Company, contracted staff)?	No
Other than the page for your Chapter on the ISPOR website, does your Chapter maintain a website?	<p>Yes</p> <p>http://www.labclinpharm.ru http://www.healtheconomics.ru</p>
Does the Chapter have a bank account?	Yes
Official organizational email address?	No
How can the ISPOR organization as a whole (Staff, Board, Consortia, Networks, etc.) better support your Chapter?	Networks
3 challenges the Chapter is facing at the start of 2018.	<p>Organise HTA education meetings</p> <p>Take part in HTA researcher</p> <p>Improving our role in making decision in HTA politics in our country</p> <p>ISPOR St. Petersburg Chapter members list_2017_final.docx</p> <p>CV engl.doc</p> <p>2018 Regional Chapter Annual Work Plan_complete.pdf</p> <p>Professor Alexey S. Kolbin, MD, PhD, Doctor of Science, Head of the department of clinical pharmacology and evidence-based medicine, Pavlov First Saint Petersburg State Medical University; alex.kolbin@mai.ru; Yulia E. Balykina, PhD, St Petersburg State University, faculty of Applied Mathematics and Control Processes, associate professor, julia.balykina@gmail.com; Alexey Kurilev, MD, Department of Clinical Pharmacology First Pavlov State Medical University of St.Peterburg; alexey-kurilev@yandex.ru</p>
Current Chapter members.	
CV for the Chapter President.	
Chapter's Annual Work Plan.	
Who prepared this report.	

FCPA Agreement

x